首页> 外文期刊>Journal of Breast Cancer >Overexpression of the Bmi-1 Oncoprotein correlates with Axillary Lymph Node Metastases in Invasive Ductal Breast Cancer
【24h】

Overexpression of the Bmi-1 Oncoprotein correlates with Axillary Lymph Node Metastases in Invasive Ductal Breast Cancer

机译:Bmi-1癌蛋白的过表达与侵袭性导管癌的腋窝淋巴结转移有关。

获取原文
           

摘要

Purpose The modulation of Bmi-1 is observed in several tumor tissues, with its heightened protein level suspected of being involved in tumorigenesis by acting as a transcriptional repressor in the INK4a/ ARF locus. To elucidate the role of Bmi-1 in invasive ductal breast cancers, the expression of Bmi-1 at the mRNA and protein levels were examined. Methods Breast carcinoma samples were obtained from patients who underwent routine surgery for breast cancer at the Department of Surgery, Chonbuk National University Hospital, in 2000-2002. Cancerous breast and paired normal breast tissues were taken from a site distant from the tumorous lesion, and analyzed with reverse transcription-polymerase chain reaction (RT-PCR) and and immunohistochemical assay. We analyzed the correlations between the expression of Bmi-1 and various clinicopathological factors, such as age, lymph node metastases, estrogen receptor (ER), and progesterone receptor (PR), in invasive ductal carcinomas of the breast. Results The Bmi-1 mRNA level by RT-PCR was shown to be significantly up-regulated in 19 of the 22 breast carcinoma tissues specimen compared with the non-neoplastic tissues adjusted to tested specimens. The immunohistochemical staining for Bmi-1 also showed high a level of expression in 44 of the 71 invasive ductal breast cancers (62%), and was more intense in the invading fronts than in the central portions of the primary invasive breast cancers. Univariate and multivariate analyses showed that a high level of Bmi-1 expression was significantly correlated with axillary lymph node metastases and a positive estrogen receptor status. Conclusion The Bmi-1 was differentially expressed in human breast carcinomas. These findings suggested that Bmi-1 might be involved in the progression of invasive ductal breast cancer, and it may be clinically useful in selecting patients who could benefit from adjuvant chemotherapy.
机译:目的在一些肿瘤组织中观察到Bmi-1的调节,其B蛋白-1的蛋白水平升高被怀疑通过在INK4a / ARF基因座中起转录阻遏物的作用而参与了肿瘤发生。为了阐明Bmi-1在浸润性导管癌中的作用,检测了Bmi-1在mRNA和蛋白质水平上的表达。方法从2000-2002年在春北国立大学医院外科接受乳腺癌常规手术的患者中获取乳腺癌样品。从远离肿瘤病变的部位取出癌性乳房和成对的正常乳房组织,并用逆转录-聚合酶链反应(RT-PCR)和免疫组织化学分析法进行分析。我们分析了乳腺浸润性导管癌中Bmi-1的表达与各种临床病理因素之间的相关性,例如年龄,淋巴结转移,雌激素受体(ER)和孕激素受体(PR)。结果与调整为测试标本的非肿瘤组织相比,通过RT-PCR的Bmi-1 mRNA水平在22个乳腺癌组织标本中的19个中显着上调。 Bmi-1的免疫组织化学染色在71种浸润性导管癌中有44个表达高水平(62%),并且在侵袭前沿比在原发性浸润性乳腺癌的中央部位更强。单因素和多因素分析表明,高水平的Bmi-1表达与腋窝淋巴结转移和雌激素受体阳性状态显着相关。结论Bmi-1在人乳腺癌中有差异表达。这些发现表明,Bmi-1可能与浸润性导管癌的发展有关,在选择可以从辅助化疗中受益的患者方面可能具有临床意义。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号